Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Lurasidone
- Accession Number
- DB08815
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. (Wikipedia)
- Structure
Structure for DB08815 (Lurasidone)
- Synonyms
- Lurasidona
- Lurasidonum
- External IDs
- SM-13496
- Product Ingredients
Ingredient UNII CAS InChI Key Lurasidone Hydrochloride O0P4I5851I 367514-88-3 NEKCRUIRPWNMLK-SCIYSFAVSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Latuda Tablet, film coated 40 mg/1 Oral Avera Mc Kennan Hospital 2015-03-02 2017-11-02 US 
Latuda Tablet, film coated 60 mg/1 Oral Sunovion 2013-07-12 Not applicable US 
Latuda Tablet 20 mg Oral Sunovion 2014-04-09 Not applicable Canada 
Latuda Tablet 80 mg Oral Sunovion 2012-09-05 Not applicable Canada Latuda Tablet, film coated 120 mg/1 Oral Sunovion 2012-04-26 Not applicable US Latuda Tablet, film coated 40 mg/1 Oral Sunovion 2010-10-28 Not applicable US 
Latuda Tablet 60 mg Oral Sunovion 2014-03-14 Not applicable Canada Latuda Tablet 40 mg Oral Sunovion 2012-09-06 Not applicable Canada Latuda Tablet, film coated 80 mg/1 Oral Sunovion 2010-10-28 Not applicable US 
Latuda Tablet, film coated 20 mg/1 Oral Sunovion 2011-12-07 Not applicable US 
- Categories
- Adrenergic Agents
- Adrenergic alpha-2 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Antipsychotic Agents
- Antipsychotic Agents (Second Generation [Atypical])
- Atypical Antipsychotic
- Atypical Antipsychotics
- Central Nervous System Agents
- Central Nervous System Depressants
- CYP3A Substrates (Sensitive)
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (weak)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Dopamine Agents
- Dopamine Antagonists
- Dopamine D2 Receptor Antagonists
- Hyperglycemia-Associated Agents
- Indole Derivatives
- Isoindoles
- Nervous System
- Neurotransmitter Agents
- Psycholeptics
- Psychotropic Drugs
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Agents
- Serotonin Antagonists
- Sulfur Compounds
- Thiazoles
- Tranquilizing Agents
- UNII
- 22IC88528T
- CAS number
- 367514-87-2
- Weight
- Average: 492.676
Monoisotopic: 492.255897106 - Chemical Formula
- C28H36N4O2S
- InChI Key
- PQXKDMSYBGKCJA-CVTJIBDQSA-N
- InChI
- InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
- IUPAC Name
- (1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0²,⁶]decane-3,5-dione
- SMILES
- O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=CC=CC=C12
Pharmacology
- Indication
Treatment of schizophrenia.
- Structured Indications
- Pharmacodynamics
Lurasidone is a benzothiazol derivative that is an antagonist and binds with high affinity to Dopamine-2 (D2) (Ki = 0.994 nM), 5-HT2A (Ki = 0.47 nM) receptors, and 5-HT7 receptors (Ki = 0.495 nM). It also binds with moderate affinity to alpha-2C adrenergic receptors (Ki = 10.8 nM) and is a partial agonist at 5-HT1A receptors (Ki = 6.38 nM). Its actions on histaminergic and muscarinic receptors are negligible.
- Mechanism of action
Lurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can improve negative symptoms of psychoses and reduce the extrapyramidal side effects that are often associated with typical antipsychotics.
Target Actions Organism AD(2) dopamine receptor antagonistHuman A5-hydroxytryptamine receptor 2A antagonistHuman U5-hydroxytryptamine receptor 7 antagonistHuman U5-hydroxytryptamine receptor 1A antagonistHuman UAlpha-2C adrenergic receptor antagonistHuman UAlpha-2A adrenergic receptor Not Available Human - Absorption
Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content.
Bioavailability = 9-19%.- Volume of distribution
6173 L
- Protein binding
~99% bound to serum proteins.
- Metabolism
Lurasidone is metabolized by CYP3A4 in which its major active metabolite is referred to as ID-14283 (25% of parent exposure). Its two minor metabolites are referred to as ID14326 and ID11614 which make up 3% and 1% of parent exposure respectively. Its two non-active metabolites are referred to as ID-20219 and ID-20220.
- Route of elimination
Urine (~9%) and feces (~80%)
- Half life
40 mg dose= 18 hours 120 mg - 160 mg dose = 29-37 hours
- Clearance
3902 mL/min
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Lurasidone. Investigational 2,5-Dimethoxy-4-ethylamphetamine Lurasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine Lurasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine. Experimental 3,4-Methylenedioxyamphetamine Lurasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine Lurasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Lurasidone is combined with 7-Nitroindazole. Experimental Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Lurasidone. Approved, Investigational Acepromazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Aceprometazine. Approved Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lurasidone. Approved, Investigational, Withdrawn Acetyl sulfisoxazole The serum concentration of Lurasidone can be increased when it is combined with Acetyl sulfisoxazole. Approved, Vet Approved Adipiplon The risk or severity of adverse effects can be increased when Lurasidone is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Lurasidone is combined with Agomelatine. Approved, Investigational AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lurasidone. Experimental, Investigational Alaproclate The risk or severity of adverse effects can be increased when Lurasidone is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Lurasidone is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Lurasidone. Approved, Illicit Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Lurasidone. Investigational Allopregnanolone The risk or severity of adverse effects can be increased when Lurasidone is combined with Allopregnanolone. Investigational Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Lurasidone. Approved, Investigational Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Lurasidone is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Lurasidone is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Lurasidone. Approved, Illicit, Investigational Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Lurasidone. Approved Amiodarone The serum concentration of Lurasidone can be increased when it is combined with Amiodarone. Approved, Investigational Amisulpride Lurasidone may increase the antipsychotic activities of Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Lurasidone is combined with Amitriptyline. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Lurasidone. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Lurasidone is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Lurasidone is combined with Amperozide. Experimental Amphetamine Lurasidone may decrease the stimulatory activities of Amphetamine. Approved, Illicit, Investigational Apalutamide The serum concentration of Lurasidone can be decreased when it is combined with Apalutamide. Approved, Investigational Apomorphine The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone. Approved, Investigational Aprepitant The serum concentration of Lurasidone can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lurasidone. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Lurasidone. Approved Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Lurasidone. Approved, Investigational, Withdrawn Atazanavir The serum concentration of Lurasidone can be increased when it is combined with Atazanavir. Approved, Investigational Atomoxetine The serum concentration of Lurasidone can be increased when it is combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Lurasidone is combined with Atorvastatin. Approved Azaperone The risk or severity of adverse effects can be increased when Lurasidone is combined with Azaperone. Investigational, Vet Approved Azelastine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Lurasidone is combined with Baclofen. Approved Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Lurasidone. Investigational Barbital The risk or severity of adverse effects can be increased when Lurasidone is combined with Barbital. Illicit Bempedoic acid The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Lurasidone. Investigational Benperidol The risk or severity of adverse effects can be increased when Lurasidone is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Benzocaine. Approved, Investigational Benzphetamine Lurasidone may decrease the stimulatory activities of Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Lurasidone is combined with Benzyl alcohol. Approved Boceprevir The serum concentration of Lurasidone can be increased when it is combined with Boceprevir. Approved, Withdrawn Bortezomib The serum concentration of Lurasidone can be increased when it is combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Lurasidone can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Lurasidone. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Lurasidone is combined with Brexpiprazole. Approved, Investigational Brigatinib The serum concentration of Lurasidone can be decreased when it is combined with Brigatinib. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Lurasidone is combined with Bromisoval. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lurasidone. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Lurasidone is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Lurasidone is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Lurasidone is combined with Brotizolam. Approved, Investigational, Withdrawn Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Lurasidone. Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Bupivacaine. Approved, Investigational Buprenorphine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Lurasidone. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Lurasidone is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Lurasidone is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Lurasidone is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone. Approved, Illicit, Vet Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Lurasidone. Approved Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone. Approved Canertinib The risk or severity of adverse effects can be increased when Lurasidone is combined with Canertinib. Investigational Carbamazepine The serum concentration of Lurasidone can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Lurasidone is combined with Carbinoxamine. Approved Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Lurasidone. Experimental Carfentanil The risk or severity of adverse effects can be increased when Lurasidone is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Lurasidone is combined with Carisoprodol. Approved Castanospermine The therapeutic efficacy of Castanospermine can be decreased when used in combination with Lurasidone. Experimental Ceritinib The serum concentration of Lurasidone can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Lurasidone. Approved, Withdrawn Cetirizine The risk or severity of adverse effects can be increased when Lurasidone is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Lurasidone is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lurasidone. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine. Approved Chlorphentermine Lurasidone may decrease the stimulatory activities of Chlorphentermine. Illicit, Withdrawn Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lurasidone. Approved, Investigational, Vet Approved Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone. Approved, Investigational Chlorprothixene The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorzoxazone. Approved Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lurasidone. Experimental Cinchocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Cinchocaine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Lurasidone is combined with Citalopram. Approved Clarithromycin The serum concentration of Lurasidone can be increased when it is combined with Clarithromycin. Approved Clemastine The serum concentration of Lurasidone can be increased when it is combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Lurasidone is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Lurasidone is combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Lurasidone is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Lurasidone is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Lurasidone is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Lurasidone is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Lurasidone. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Lurasidone is combined with Clothiapine. Experimental Clotrimazole The serum concentration of Lurasidone can be increased when it is combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Lurasidone. Approved Cobicistat The serum concentration of Lurasidone can be increased when it is combined with Cobicistat. Approved Cocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Lurasidone. Approved, Illicit Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Lurasidone. Approved, Investigational Crizotinib The serum concentration of Lurasidone can be increased when it is combined with Crizotinib. Approved Cyclizine The risk or severity of adverse effects can be increased when Lurasidone is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone. Approved Cyclopropane The risk or severity of adverse effects can be increased when Lurasidone is combined with Cyclopropane. Experimental Cyclosporine The serum concentration of Lurasidone can be increased when it is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Lurasidone is combined with Cyproheptadine. Approved Dabrafenib The serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Lurasidone is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Lurasidone is combined with Dapoxetine. Investigational Darunavir The serum concentration of Lurasidone can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Lurasidone can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Lurasidone can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The serum concentration of Lurasidone can be increased when it is combined with Delavirdine. Approved Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Lurasidone. Investigational Deramciclane The risk or severity of adverse effects can be increased when Lurasidone is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Lurasidone. Approved Desipramine The risk or severity of adverse effects can be increased when Lurasidone is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Lurasidone is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Lurasidone is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Dexmedetomidine. Approved, Vet Approved Dextroamphetamine Lurasidone may decrease the stimulatory activities of Dextroamphetamine. Approved, Illicit Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lurasidone. Approved Dextromoramide The risk or severity of adverse effects can be increased when Lurasidone is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Lurasidone is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Lurasidone is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Lurasidone. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Lurasidone is combined with Diethyl ether. Experimental Diethylpropion Lurasidone may decrease the stimulatory activities of Diethylpropion. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Lurasidone is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lurasidone. Approved, Illicit Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lurasidone. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lurasidone. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Lurasidone. Experimental Dihydroergotamine The serum concentration of Lurasidone can be increased when it is combined with Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Lurasidone is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Lurasidone is combined with Dihydromorphine. Experimental, Illicit Diltiazem The serum concentration of Lurasidone can be increased when it is combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Lurasidone is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lurasidone. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone. Approved, Illicit Disopyramide Lurasidone may increase the QTc-prolonging activities of Disopyramide. Approved Dixyrazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Dixyrazine. Experimental Dopamine Dopamine may increase the hypotensive activities of Lurasidone. Approved Doramectin The risk or severity of adverse effects can be increased when Lurasidone is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Lurasidone is combined with Doxepin. Approved, Investigational Doxycycline The serum concentration of Lurasidone can be increased when it is combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Lurasidone is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved, Illicit Dronedarone The serum concentration of Lurasidone can be increased when it is combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Lurasidone is combined with Drotebanol. Experimental, Illicit Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lurasidone. Approved, Investigational Duloxetine The risk or severity of adverse effects can be increased when Lurasidone is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Lurasidone is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Lurasidone is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Lurasidone is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Lurasidone is combined with Efavirenz. Approved, Investigational Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Lurasidone. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Lurasidone is combined with Eltanolone. Investigational Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone. Approved Enflurane The risk or severity of adverse effects can be increased when Lurasidone is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Lurasidone is combined with Entacapone. Approved, Investigational Enzalutamide The serum concentration of Lurasidone can be decreased when it is combined with Enzalutamide. Approved Epinephrine Epinephrine may increase the hypotensive activities of Lurasidone. Approved, Vet Approved Ergoloid mesylate The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Lurasidone. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Lurasidone. Approved Erythromycin The serum concentration of Lurasidone can be increased when it is combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram The risk or severity of adverse effects can be increased when Lurasidone is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Lurasidone. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Lurasidone. Approved, Investigational Ethanol Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Lurasidone is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Lurasidone is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Lurasidone is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Lurasidone is combined with Etorphine. Illicit, Vet Approved Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Lurasidone. Approved, Investigational Ezogabine The risk or severity of adverse effects can be increased when Lurasidone is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Lurasidone is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Lurasidone is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Lurasidone is combined with Fexofenadine. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Lurasidone is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Lurasidone is combined with Fluanisone. Experimental Fluconazole The serum concentration of Lurasidone can be increased when it is combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Lurasidone is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Lurasidone is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Lurasidone is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Lurasidone is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Lurasidone is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Lurasidone is combined with Fluticasone propionate. Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Lurasidone. Approved Fluvoxamine The serum concentration of Lurasidone can be increased when it is combined with Fluvoxamine. Approved, Investigational Fosamprenavir The serum concentration of Lurasidone can be increased when it is combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Lurasidone can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Lurasidone can be decreased when it is combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Lurasidone is combined with Fospropofol. Approved, Illicit, Investigational Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Lurasidone. Approved, Investigational Fusidic Acid The serum concentration of Lurasidone can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Lurasidone is combined with Gabapentin Enacarbil. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lurasidone. Approved, Illicit, Investigational Gepefrine Lurasidone may decrease the stimulatory activities of Gepefrine. Experimental Gepirone The risk or severity of adverse effects can be increased when Lurasidone is combined with Gepirone. Investigational Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Lurasidone. Investigational, Withdrawn Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Lurasidone. Approved Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone. Approved Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Lurasidone. Approved, Investigational Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Lurasidone. Approved, Investigational Glutethimide The risk or severity of adverse effects can be increased when Lurasidone is combined with Glutethimide. Approved, Illicit Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Lurasidone. Approved Guanfacine The risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine. Approved, Investigational Gusperimus The therapeutic efficacy of Gusperimus can be decreased when used in combination with Lurasidone. Investigational Halazepam The risk or severity of adverse effects can be increased when Lurasidone is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone. Approved Halothane The risk or severity of adverse effects can be increased when Lurasidone is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Lurasidone is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Lurasidone is combined with Hexobarbital. Approved Hydrocodone Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone. Approved, Illicit Hydroxyamphetamine Lurasidone may decrease the stimulatory activities of Hydroxyamphetamine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Lurasidone. Approved Idelalisib The serum concentration of Lurasidone can be increased when it is combined with Idelalisib. Approved Iloperidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Iloperidone. Approved Imatinib The serum concentration of Lurasidone can be increased when it is combined with Imatinib. Approved Imipramine The risk or severity of adverse effects can be increased when Lurasidone is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Lurasidone is combined with Indalpine. Investigational, Withdrawn Indinavir The serum concentration of Lurasidone can be increased when it is combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Lurasidone is combined with Indiplon. Investigational Insulin Aspart The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lurasidone. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lurasidone. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lurasidone. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lurasidone. Approved Insulin Human The therapeutic efficacy of Insulin Human can be decreased when used in combination with Lurasidone. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lurasidone. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lurasidone. Approved Iofetamine I-123 Lurasidone may decrease the stimulatory activities of Iofetamine I-123. Approved Isavuconazole The serum concentration of Lurasidone can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The serum concentration of Lurasidone can be increased when it is combined with Isavuconazonium. Approved, Investigational Isocarboxazid The therapeutic efficacy of Lurasidone can be increased when used in combination with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Lurasidone. Approved, Vet Approved Isradipine The serum concentration of Lurasidone can be increased when it is combined with Isradipine. Approved, Investigational Itraconazole The serum concentration of Lurasidone can be increased when it is combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Lurasidone can be increased when it is combined with Ivacaftor. Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Lurasidone. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Lurasidone is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Ketobemidone. Approved, Investigational Ketoconazole The serum concentration of Lurasidone can be increased when it is combined with Ketoconazole. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lurasidone is combined with Lamotrigine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Lurasidone is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Lurasidone is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Lurasidone is combined with Levocetirizine. Approved Levodopa The therapeutic efficacy of Levodopa can be decreased when used in combination with Lurasidone. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Lurasidone is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Lurasidone is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Lurasidone. Approved Lidocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Lidocaine. Approved, Vet Approved Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lurasidone. Approved Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Lurasidone. Approved, Investigational Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Lurasidone. Approved Lisdexamfetamine Lurasidone may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Lurasidone. Approved, Investigational Lithium Lithium may increase the neurotoxic activities of Lurasidone. Approved Lofentanil The risk or severity of adverse effects can be increased when Lurasidone is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Lurasidone can be increased when used in combination with Lofexidine. Approved, Investigational Lopinavir The serum concentration of Lurasidone can be increased when it is combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Lurasidone is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Lurasidone is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Lurasidone. Approved Lorcaserin The risk or severity of adverse effects can be increased when Lorcaserin is combined with Lurasidone. Approved Lormetazepam The risk or severity of adverse effects can be increased when Lurasidone is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Lurasidone can be increased when it is combined with Lorpiprazole. Approved Lovastatin The serum concentration of Lurasidone can be increased when it is combined with Lovastatin. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone. Approved Luliconazole The serum concentration of Lurasidone can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Lurasidone can be decreased when it is combined with Lumacaftor. Approved Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Lurasidone. Illicit, Investigational, Withdrawn Magnesium sulfate The therapeutic efficacy of Lurasidone can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Lurasidone is combined with Maprotiline. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Lurasidone is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Lurasidone is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Lurasidone is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Lurasidone is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Lurasidone is combined with Melperone. Approved, Investigational Mephedrone Lurasidone may decrease the stimulatory activities of Mephedrone. Investigational Mephentermine Lurasidone may decrease the stimulatory activities of Mephentermine. Approved Mepivacaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Lurasidone is combined with Meptazinol. Experimental Mequitazine Lurasidone may increase the arrhythmogenic activities of Mequitazine. Approved Mesoridazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone. Approved Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Lurasidone. Experimental Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Lurasidone is combined with Methadyl Acetate. Approved, Illicit Methamphetamine Lurasidone may decrease the stimulatory activities of Methamphetamine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Lurasidone is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Lurasidone is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Lurasidone. Approved Methotrimeprazine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Lurasidone is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methoxyphenamine Lurasidone may decrease the stimulatory activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylecgonine. Experimental Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lurasidone. Approved Methylphenidate The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate. Approved, Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenobarbital. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Lurasidone. Approved Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone. Approved, Investigational Metyrosine Lurasidone may increase the sedative activities of Metyrosine. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Lurasidone. Experimental Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone. Approved, Illicit Midomafetamine Lurasidone may decrease the stimulatory activities of Midomafetamine. Experimental, Illicit, Investigational Mifepristone The serum concentration of Lurasidone can be increased when it is combined with Mifepristone. Approved, Investigational Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Lurasidone. Approved Miglustat The therapeutic efficacy of Miglustat can be decreased when used in combination with Lurasidone. Approved Milnacipran The risk or severity of adverse effects can be increased when Lurasidone is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved, Investigational Mirtazapine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lurasidone. Approved, Investigational Mitotane The serum concentration of Lurasidone can be decreased when it is combined with Mitotane. Approved MMDA Lurasidone may decrease the stimulatory activities of MMDA. Experimental, Illicit Moclobemide The risk or severity of adverse effects can be increased when Moclobemide is combined with Lurasidone. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Lurasidone is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Lurasidone. Approved Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Lurasidone. Approved, Investigational Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Lurasidone. Approved, Investigational Nefazodone The serum concentration of Lurasidone can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Lurasidone can be increased when it is combined with Nelfinavir. Approved Netupitant The serum concentration of Lurasidone can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The serum concentration of Lurasidone can be decreased when it is combined with Nevirapine. Approved Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Lurasidone. Approved, Investigational Nilotinib The serum concentration of Lurasidone can be increased when it is combined with Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Lurasidone. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lurasidone. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Lurasidone is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Lurasidone is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Lurasidone is combined with Nortriptyline. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Lurasidone. Approved, Investigational Olaparib The serum concentration of Lurasidone can be increased when it is combined with Olaparib. Approved Olopatadine The risk or severity of adverse effects can be increased when Lurasidone is combined with Olopatadine. Approved Ondansetron The risk or severity of adverse effects can be increased when Lurasidone is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Lurasidone is combined with Opium. Approved, Illicit Orphenadrine Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Lurasidone is combined with Osanetant. Investigational Osimertinib The serum concentration of Lurasidone can be increased when it is combined with Osimertinib. Approved Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Lurasidone. Approved Oxetacaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Oxetacaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Lurasidone is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lurasidone. Approved, Investigational, Vet Approved Palbociclib The serum concentration of Lurasidone can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Lurasidone. Approved Paraldehyde Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Lurasidone is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Lurasidone is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone. Approved, Vet Approved Pentobarbital The serum concentration of Lurasidone can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved Perazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Perazine. Approved, Investigational Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Lurasidone. Approved, Investigational, Vet Approved, Withdrawn Perospirone The risk or severity of adverse effects can be increased when Lurasidone is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Lurasidone. Approved Phenazocine The risk or severity of adverse effects can be increased when Lurasidone is combined with Phenazocine. Experimental Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Lurasidone. Approved Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Lurasidone. Approved, Investigational, Withdrawn Phenibut The risk or severity of adverse effects can be increased when Lurasidone is combined with Phenibut. Experimental Phenobarbital The serum concentration of Lurasidone can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Lurasidone is combined with Phenoxyethanol. Approved Phentermine Lurasidone may decrease the stimulatory activities of Phentermine. Approved, Illicit Phenytoin The serum concentration of Lurasidone can be decreased when it is combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Lurasidone. Approved Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lurasidone. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Lurasidone is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Pipotiazine. Approved, Investigational Piribedil The therapeutic efficacy of Piribedil can be decreased when used in combination with Lurasidone. Investigational Piritramide The risk or severity of adverse effects can be increased when Lurasidone is combined with Piritramide. Approved, Investigational Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Lurasidone. Approved Pitolisant The serum concentration of Lurasidone can be decreased when it is combined with Pitolisant. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Lurasidone is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide. Approved Posaconazole The serum concentration of Lurasidone can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole Lurasidone may increase the sedative activities of Pramipexole. Approved, Investigational Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Lurasidone. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Pramocaine. Approved Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Lurasidone. Approved Prazepam The risk or severity of adverse effects can be increased when Lurasidone is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Lurasidone can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Prilocaine. Approved Primidone The serum concentration of Lurasidone can be decreased when it is combined with Primidone. Approved, Vet Approved Procainamide Lurasidone may increase the QTc-prolonging activities of Procainamide. Approved Procaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Procaine. Approved, Investigational, Vet Approved Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone. Approved, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Promethazine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Lurasidone is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Lurasidone is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Lurasidone is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Lurasidone is combined with PSD502. Investigational Pseudoephedrine Lurasidone may decrease the stimulatory activities of Pseudoephedrine. Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Lurasidone. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone. Approved Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Lurasidone. Approved, Investigational Quinidine Lurasidone may increase the QTc-prolonging activities of Quinidine. Approved, Investigational Quinisocaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Lurasidone is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Lurasidone is combined with Ramelteon. Approved, Investigational Ranolazine The serum concentration of Lurasidone can be increased when it is combined with Ranolazine. Approved, Investigational Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Lurasidone. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Lurasidone. Approved Remoxipride The risk or severity of adverse effects can be increased when Lurasidone is combined with Remoxipride. Approved, Withdrawn Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lurasidone. Approved, Investigational Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Lurasidone. Approved, Investigational Ribociclib The serum concentration of Lurasidone can be increased when it is combined with Ribociclib. Approved, Investigational Rifabutin The serum concentration of Lurasidone can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Lurasidone can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Lurasidone can be decreased when it is combined with Rifapentine. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Lurasidone. Approved Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Lurasidone is combined with Ritanserin. Investigational Ritobegron Lurasidone may decrease the stimulatory activities of Ritobegron. Investigational Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Lurasidone. Approved Romifidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Romifidine. Vet Approved Ropinirole Lurasidone may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Ropivacaine. Approved Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lurasidone. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Lurasidone. Approved Rotigotine Lurasidone may increase the sedative activities of Rotigotine. Approved Rucaparib The serum concentration of Lurasidone can be increased when it is combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Lurasidone. Approved Saquinavir The serum concentration of Lurasidone can be increased when it is combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Lurasidone can be decreased when used in combination with Sarilumab. Approved, Investigational Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lurasidone. Approved Scopolamine The risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Lurasidone. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Lurasidone is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Lurasidone is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Lurasidone is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lurasidone. Approved, Vet Approved Sildenafil The serum concentration of Lurasidone can be increased when it is combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Lurasidone can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Lurasidone can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Lurasidone. Approved Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lurasidone. Approved, Investigational Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lurasidone. Investigational St. John's Wort The serum concentration of Lurasidone can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Lurasidone can be increased when it is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone. Approved, Investigational Sulfisoxazole The serum concentration of Lurasidone can be increased when it is combined with Sulfisoxazole. Approved, Vet Approved Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Lurasidone. Approved, Investigational Sulpiride Lurasidone may increase the antipsychotic activities of Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Lurasidone is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Lurasidone. Approved, Investigational Suvorexant Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Lurasidone is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. Approved Tasimelteon The risk or severity of adverse effects can be increased when Lurasidone is combined with Tasimelteon. Approved, Investigational Tedizolid Phosphate The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Lurasidone. Approved Telaprevir The serum concentration of Lurasidone can be increased when it is combined with Telaprevir. Approved, Withdrawn Telithromycin The serum concentration of Lurasidone can be increased when it is combined with Telithromycin. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Lurasidone. Approved, Investigational Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Lurasidone. Experimental Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lurasidone. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Lurasidone is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrodotoxin. Investigational Thalidomide Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Lurasidone is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Lurasidone is combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Lurasidone. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone. Approved Tiagabine The risk or severity of adverse effects can be increased when Lurasidone is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Lurasidone is combined with Tiapride. Approved, Investigational Ticlopidine The serum concentration of Lurasidone can be increased when it is combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Lurasidone is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine. Approved, Investigational Tocilizumab The serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab. Approved Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Lurasidone. Approved, Investigational Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lurasidone. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Lurasidone is combined with Tolcapone. Approved, Withdrawn Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Lurasidone. Approved Topiramate The risk or severity of adverse effects can be increased when Lurasidone is combined with Topiramate. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Lurasidone. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Lurasidone is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Lurasidone is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Lurasidone. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Lurasidone is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Lurasidone is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lurasidone. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Lurasidone is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Lurasidone is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Triprolidine. Approved Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Lurasidone. Investigational, Withdrawn Valproic Acid The risk or severity of adverse effects can be increased when Lurasidone is combined with Valproic Acid. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lurasidone. Approved Venlafaxine The serum concentration of Lurasidone can be increased when it is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Lurasidone is combined with Veralipride. Experimental Verapamil The serum concentration of Lurasidone can be increased when it is combined with Verapamil. Approved Vigabatrin The risk or severity of adverse effects can be increased when Lurasidone is combined with Vigabatrin. Approved Vilazodone The risk or severity of adverse effects can be increased when Vilazodone is combined with Lurasidone. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lurasidone. Approved, Investigational Vinyl ether The risk or severity of adverse effects can be increased when Lurasidone is combined with Vinyl ether. Experimental Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Lurasidone. Approved, Investigational Voriconazole The serum concentration of Lurasidone can be increased when it is combined with Voriconazole. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Lurasidone is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Lurasidone is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Lurasidone is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Lurasidone is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Lurasidone is combined with Zimelidine. Withdrawn Ziprasidone The serum concentration of Lurasidone can be increased when it is combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Lurasidone is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lurasidone. Approved, Investigational Zolpidem Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Lurasidone is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Lurasidone. Approved Zotepine The risk or severity of adverse effects can be increased when Lurasidone is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone. Approved, Investigational - Food Interactions
- When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours.
References
- General References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
- Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428]
- External Links
- KEGG Drug
- D04820
- PubChem Compound
- 213046
- PubChem Substance
- 175427100
- ChemSpider
- 184739
- BindingDB
- 85222
- ChEBI
- 70735
- ChEMBL
- CHEMBL1237021
- PharmGKB
- PA166129557
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Lurasidone
- ATC Codes
- N05AE05 — Lurasidone
- AHFS Codes
- 28:16.08.04 — Atypical Antipsychotics
- FDA label
- Download (452 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Tablet Oral 120 mg Tablet Oral 20 mg Tablet Oral 40 mg Tablet Oral 60 mg Tablet Oral 80 mg Tablet, film coated Oral 120 mg/1 Tablet, film coated Oral 20 mg/1 Tablet, film coated Oral 40 mg/1 Tablet, film coated Oral 60 mg/1 Tablet, film coated Oral 80 mg/1 - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US9174975 Yes 2006-12-25 2026-12-25 US US9259423 Yes 2011-11-23 2031-11-23 US US8729085 Yes 2006-11-26 2026-11-26 US US5532372 Yes 1999-01-02 2019-01-02 US US8883794 Yes 2006-11-26 2026-11-26 US USRE45573 Yes 2005-12-23 2025-12-23 US US9555027 No 2006-05-26 2026-05-26 US US9815827 No 2004-02-20 2024-02-20 US US9827242 No 2011-05-23 2031-05-23 US US9907794 No 2006-05-26 2026-05-26 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00789 mg/mL ALOGPS logP 5.25 ALOGPS logP 4.56 ChemAxon logS -4.8 ALOGPS pKa (Strongest Basic) 8.5 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 56.75 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 139.33 m3·mol-1 ChemAxon Polarizability 56.2 Å3 ChemAxon Number of Rings 7 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9907 Caco-2 permeable + 0.5257 P-glycoprotein substrate Substrate 0.6029 P-glycoprotein inhibitor I Inhibitor 0.6713 P-glycoprotein inhibitor II Inhibitor 0.73 Renal organic cation transporter Inhibitor 0.5487 CYP450 2C9 substrate Non-substrate 0.7897 CYP450 2D6 substrate Substrate 0.8918 CYP450 3A4 substrate Substrate 0.5922 CYP450 1A2 substrate Non-inhibitor 0.677 CYP450 2C9 inhibitor Inhibitor 0.6714 CYP450 2D6 inhibitor Non-inhibitor 0.8292 CYP450 2C19 inhibitor Inhibitor 0.7439 CYP450 3A4 inhibitor Non-inhibitor 0.7835 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8126 Ames test Non AMES toxic 0.6477 Carcinogenicity Non-carcinogens 0.8986 Biodegradation Not ready biodegradable 0.9959 Rat acute toxicity 2.4051 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6636 hERG inhibition (predictor II) Inhibitor 0.5858
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- N-arylpiperazines
- Alternative Parents
- Aromatic monoterpenoids / Isoindolones / Benzothiazoles / Dialkylarylamines / N-alkylpiperazines / Aminothiazoles / Benzenoids / Pyrrolidine-2-ones / Imidolactams / N-substituted carboxylic acid imides show 11 more
- Substituents
- N-arylpiperazine / Aromatic monoterpenoid / Monoterpenoid / Norbornane monoterpenoid / Isoindolone / 1,2-benzothiazole / Isoindoline / Isoindole or derivatives / Dialkylarylamine / N-alkylpiperazine show 29 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- N-arylpiperazine, dicarboximide, bridged compound, 1,2-benzisothiazole (CHEBI:70735)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Virus receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
- Gene Name
- HTR2A
- Uniprot ID
- P28223
- Uniprot Name
- 5-hydroxytryptamine receptor 2A
- Molecular Weight
- 52602.58 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
- Gene Name
- HTR7
- Uniprot ID
- P34969
- Uniprot Name
- 5-hydroxytryptamine receptor 7
- Molecular Weight
- 53554.43 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
- Gene Name
- HTR1A
- Uniprot ID
- P08908
- Uniprot Name
- 5-hydroxytryptamine receptor 1A
- Molecular Weight
- 46106.335 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein homodimerization activity
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
- Gene Name
- ADRA2C
- Uniprot ID
- P18825
- Uniprot Name
- Alpha-2C adrenergic receptor
- Molecular Weight
- 49521.585 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
- Gene Name
- ADRA2A
- Uniprot ID
- P08913
- Uniprot Name
- Alpha-2A adrenergic receptor
- Molecular Weight
- 48956.275 Da
References
- Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
Drug created on July 24, 2011 11:04 / Updated on May 26, 2018 08:58